Regression–Based Diagnostic Models for Early Lung Cancer Integrating Conventional Indicators with Tumor Markers
-
Published:2024-06-06
Issue:3
Volume:12
Page:20-27
-
ISSN:2330-8133
-
Container-title:American Journal of Clinical and Experimental Medicine
-
language:en
-
Short-container-title:AJCEM
Author:
Zhou Shufang1, Ge Xiaojun1, Yang Zhifang1, Zeng Fei1
Affiliation:
1. Department of Laboratory Medicine, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China; School of Laboratory Medicine, Zunyi Medical University, Zunyi, China
Abstract
The aim of this research was to develop a lung cancer diagnostic and predictive model that integrates traditional laboratory indicators with tumor markers. This model is intended to facilitate early screening and assist in the process of identifying or detecting lung cancer through a cost-effective, rapid, and convenient approach, ultimately enhancing the early detection rate of lung cancer. A retrospective study was conducted on 66 patients diagnosed with lung cancer and 159 patients with benign pulmonary conditions. Data including general clinical information, conventional laboratory test results, and tumor marker levels were collected. Data analysis was conducted using SPSS 26.0 (Statistical Product and Service Solutions 26.0). The lung cancer diagnosis and prediction model is created using a composite index established through binary logistic regression. The combined diagnostic prediction models, incorporating both traditional indicators and tumor markers, demonstrated a greater area under the curve (AUC) when compared to the diagnostic prediction model based solely on tumor markers and their combination testing. The values of cut-off point, AUC, accuracy, sensitivity, specificity, positive and negative detection rate and accuracy rate are 0.1805, 0.959, 86.67%, 0.955, 0.830, 95.45%, 83.02% and 89.33 respectively and it is shown that the combined diagnostic model display notable efficacy and clinical relevance in aiding the early diagnosis of lung cancer.
Publisher
Science Publishing Group
Reference19 articles.
1. Leiter, A., Veluswamy, R. R., and Wisnivesky, J. P. (2023). The global burden of lung cancer: current status and future trends. Nature reviews. Clinical oncology, 20(9), 624–639. https://doi.org/10.1038/s41571-023-00798-3 2. Sung, H., Ferlay, J., Siegel, R., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021, 71(3): 209-249. https://doi.org/10.3322/caac.21660 (Epub 2021 Feb 4). 3. Asakura, K., Kadota, T., Matsuzaki, J., Yoshida, Y., Yamamoto, Y., Nakagawa, K., Takizawa, S., Aoki, Y., Nakamura, E., Miura, J., Sakamoto, H., Kato, K., Watanabe, S. and Ochiya, T. A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. Commun Biol. 2020, 3: 134. https://doi.org/10.1038/s42003-020-0863-y 4. Chansky, K., Detterbeck, F., Nicholson, A., Rusch V., Vallières, E., Groome, P., Kennedy, C., Krasnik, M., Peake, M., Shemanski, L., Bolejack, V., Crowley, J., Asamura, H. and Rami-Porta, R. The IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017, 12: 1109–21. https://doi.org/10.1016/j.jtho.2017.04.011 5. Landy, R., Wang, V. L., Baldwin, D. R., Pinsky, P. F., Cheung, L. C., Castle, P. E., Skarzynski, M., Robbins, H. A., and Katki, H. A. Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals. JAMA network open, 2023, 6(3), e233273. https://doi.org/10.1001/jamanetworkopen.2023.3273
|
|